Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept, cyclophosphamide, and tacrolimus for GvHD prevention in HSCT
NCT04503616Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in graft-versus-host disease (GVHD), sponsored by NYU Langone Health. Started Sep 2020; status: completed.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04503616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503616.